Simvastain affects TAFI and thrombomodulin in CAPD patients.
Małyszko
J
J
Małyszko
J S
JS
Hryszko
T
T
Myśliwiec
M
M
D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers; D001798:Blood Proteins / Q000032:analysis; D025901:Carboxypeptidase B2 / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018180:Thrombomodulin / Q000032:analysis*; D019851:Thrombophilia / Q000209:etiology / Q000517:prevention & control
D000924:Anticholesteremic Agents; D015415:Biomarkers; D001798:Blood Proteins; D008078:Cholesterol, LDL; D005338:Fibrin Fibrinogen Degradation Products; D008055:Lipids; D008074:Lipoproteins; D018180:Thrombomodulin; D019821:Simvastatin; D025901:Carboxypeptidase B2